Clinical practice guidelines for the care and treatment of breast cancer: Follow-up after treatment for breast cancer (summary of the 2005 update)

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 10, 2005, Pages 1319-1320

  Grunfeld, Eva ^a,b   Dhesy Thind, Sukhbinder ^c,d   Levine, Mark ^d,e  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Cancer Care Nova Scotia   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; FOLLOW UP; HIGH RISK PATIENT; HISTORY OF MEDICINE; HUMAN; MAMMOGRAPHY; NOTE; OSTEOPOROSIS; PRACTICE GUIDELINE; WEIGHT GAIN;

EID: 19744369572     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.045062     Document Type: Note

References (7)

1. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer. A Canadian consensus document. 9. Follow-up after treatment for breast cancer. CAMJ 1998;158(3 Suppl):S65-70.
2. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002;20:1128-43.
3. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamouonas EP. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 2003;95:1467-76.
4. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15:1341-7.
5. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
6. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of letrozole versus placebo on bone mineral density in women completing ≥ 5 years (yrs) of adjuvant tamoxifen: NCIC CTG MA.17b [abstract]. Breast Cancer Res Treat 2004;88(Suppl 1):S36.
7. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer, understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-14.